Preimplantation genetic diagnosis (PGD) is a procedure used prior to implantation to help identify genetic defects within embryos. This serves to prevent certain geneticdiseases or disorders from being passed on to the child.

Highlights

The global Preimplantation Genetic Diagnostics (PGD) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Preimplantation Genetic Diagnostics (PGD) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Preimplantation Genetic Diagnostics (PGD) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Preimplantation Genetic Diagnostics (PGD) in Fertility Clinics is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Preimplantation Genetic Diagnostics (PGD) include Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Perkinelmer, Inc., Cooper Surgical, ABBott Laboratories, Natera, Inc., Rubicon Genomics and Oxford Gene Technology, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Preimplantation Genetic Diagnostics (PGD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Preimplantation Genetic Diagnostics (PGD).

The Preimplantation Genetic Diagnostics (PGD) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Preimplantation Genetic Diagnostics (PGD) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Preimplantation Genetic Diagnostics (PGD) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.


By Company


Illumina, Inc.

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

Perkinelmer, Inc.

Cooper Surgical

ABBott Laboratories

Natera, Inc.

Rubicon Genomics

Oxford Gene Technology

Yikon Genomics

Scigene

Beijing Genomics Institute (BGI)

Genea Limited

Hamilton Thorne

FUJIFILM Irvine Scientific

Nidacon International

Vitrolife AB

Merck

INVO Bioscience

IVFtech

Gonagen Medikal

Cook Medical

CellCura


Segment by Type


Preimplantation Genetic Screening

Preimplantation Genetic Diagnosis


Segment by Application


Fertility Clinics

Academic Medical Centers

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Preimplantation Genetic Diagnostics (PGD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.